Alexion Pharmaceuticals, Inc. is a biopharmaceutical company that was founded in 1992 and is headquartered in Connecticut, United States.

CSPC Pharmaceutical Group Ltd. is a pharmaceutical organization based in Hong Kong SAR, China. It was founded in 1997 and has since become a prominent player in the biomedicine industry.

The potential use of mannose as a supplement to inhibit gasdermin-mediated pyroptosis by activating AMPK, as described in the study published on Cell Research, presents a novel and promising avenue for the development of cancer treatments, offering a promising approach to mitigating the harsh side effects of chemotherapy.

Ipsen SA is a pharmaceutical organization that was founded in 1929 and is based in France.

Aurobindo Pharma Ltd. is a pharmaceutical organization that was founded in 1986 and is based in Andhra Pradesh, India.

YTH domain-containing family protein 1 (YTHDF1) is a translation-promoting m6A reader that targets mRNAs in the cytoplasm and contributes to tumor progression by regulating cell proliferation, DNA damage, and immunity.

STADA Arzneimittel AG is a pharmaceutical organization that was founded in 1895 and is based in Hessen, Germany.

Jazz Pharmaceuticals Plc is a pharmaceutical company that was founded in 2003 and is headquartered in Dublin, Ireland.

Fucoidan-based nanocarriers can actively transport therapeutic cargo across tumor endothelium, allowing for targeted delivery to the tumor microenvironment. This approach holds immense potential to revolutionize therapeutic outcomes for diseases with an intact BBB, such as SHH-MB, and could usher in a new era of improved therapies for a multitude of brain diseases.

They have gained broad potential in preclinical and clinical investigations in a variety of tumor types following regulatory approval of newly developed technologies involving bispecific and multispecific antibodies.

the discovery and development of USP1 inhibitors certainly open up new frontiers for the treatment of a variety of diseases, including cancer, diabetes, and potentially even more.

In order to address the risk of missed detection brought by degenerate sequences, the Patsnap Engineering team utilizes its self-developed NLP, CV, entity recognition, anaphora resolution and other technologies to construct a deep learning model.